Insmed (NASDAQ:INSM) Hits New 12-Month High – Should You Buy?

Insmed, Inc. (NASDAQ:INSM) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $209.77 and last traded at $209.02, with a volume of 2093177 shares trading hands. The stock had previously closed at $206.93.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on INSM shares. Morgan Stanley raised their price objective on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Cowen reiterated a “buy” rating on shares of Insmed in a research note on Thursday, November 20th. William Blair started coverage on shares of Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating for the company. Wells Fargo & Company upped their price target on shares of Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.53.

Insmed Trading Down 2.2%

The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $172.67 and its two-hundred day moving average is $128.67. The stock has a market cap of $43.62 billion, a price-to-earnings ratio of -35.82 and a beta of 1.05.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s revenue was up 52.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity

In other news, Director Elizabeth M. Anderson sold 10,000 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the transaction, the director owned 63,729 shares of the company’s stock, valued at approximately $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the transaction, the insider owned 54,902 shares of the company’s stock, valued at $10,089,889.56. This represents a 33.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 257,922 shares of company stock worth $44,556,283 over the last 90 days. Insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Darwin Global Management Ltd. increased its stake in shares of Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares during the period. Vanguard Group Inc. boosted its position in shares of Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after buying an additional 219,131 shares in the last quarter. Capital International Investors increased its position in Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares during the period. Finally, Artisan Partners Limited Partnership increased its position in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.